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Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the 20 
TNF family, which preferentially induces apoptosis in cells that have undergone 21 
malignant transformation. In humans, non-neoplastic cells are normally protected 22 
from the effects of TRAIL by expressing decoy receptors, lacking death domains. In 23 
contrast, neoplastic cells tend to downregulate their decoy receptor expression, 24 
increasing their susceptibility to the pro-apoptotic effects of TRAIL, via the functional 25 
TRAIL receptors. The aim of the current study was to investigate the effect of TRAIL 26 
on the canine C2 mastocytoma cell line to determine whether this agent might be a 27 
suitable treatment for mast cell tumors in dogs. 28 
C2 and MDCK cells were cultured with recombinant human TRAIL. 29 
Apoptosis was assessed using a Caspase 3 & 7 chemiluminescence assay and flow 30 
cytometry following Annexin V:FITC labelling. Cell metabolism was assessed using 31 
a colorimetric MTT-based assay. C2 cells demonstrated greater sensitivity to TRAIL-32 
induced apoptosis compared to MDCK cells by all assessment methods. The dog 33 
genome assembly was searched for orthologs of TRAIL and its receptors using 34 
published sequences from other species for reference. Although a canine ortholog for 35 
TRAIL was identified, only one TRAIL receptor ortholog (TNFRSF11B) could be 36 
found. C2, but not MDCK, cells expressed mRNA for TNFRSF11B, detected by RT-37 
PCR. In other species, TNFRSF11B is a decoy receptor, as even though it has a death 38 
domain it is secreted due to its lack of a transmembrane domain. The effect of TRAIL 39 
on the C2 cell line suggests that this cytokine might be suitable for treatment of mast 40 
cell tumors in dogs. 41 
42 
1. Introduction 43 
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, TNFSF10, Apo2L, 44 
CD253) is a relatively newly discovered member of the TNF family. TRAIL binds to 45 
specific receptors (primarily TNFRSF10 family members) expressed on the cell 46 
surface (Wiley et al., 1995, Pitti et al., 1996). In human beings, five TRAIL receptors 47 
have been identified (LeBlanc and Ashkenazi, 2003). Two of these (TNFRSF10A & 48 
B) are functional and, upon ligation with TRAIL, induce a pro-apoptotic signal via 49 
their intracellular death domains. This occurs chiefly through the extrinsic apoptotic 50 
pathway, but with some involvement of the intrinsic pathway (Pan et al., 1997, 51 
Schneider et al., 1997, Li et al., 1998). Two further receptors (TNFRSF10C & D) are 52 
also expressed on the cell surface but, due to their lack of complete death domains, 53 
they function as decoy receptors (Sheridan et al., 1997, Pan et al., 1998). TNFRSF11B 54 
(osteoprotegerin), which can also bind to TRAIL, expresses a death domain, but due 55 
to its lack of a transmembrane domain, it functions as a secreted decoy receptor 56 
(Simonet et al., 1997). 57 
In humans, non-neoplastic cells tend to be resistant to the effects of TRAIL, 58 
due to their expression of all five TNFRSF10 receptors, whereas neoplastic cells tend 59 
to downregulate their expression of decoy receptors, increasing their sensitivity to 60 
TRAIL-induced apoptosis via the functional receptors (LeBlanc and Ashkenazi, 61 
2003). Following extracellular receptor binding by TRAIL, a number of proteins are 62 
involved in intracellular signaling and their interaction determines the fate of the 63 
individual cell (Fulda et al., 2002, Ricci et al., 2004, Spee et al., 2006). Soluble 64 
recombinant human (rh)TRAIL has been shown to be effective against human tumor 65 
cells of several lineages both in vitro and in vivo (Ashkenazi et al., 1999, Walczak et 66 
al., 1999) and TRAIL-based therapy has been applied in vivo in phase I and II human 67 
clinical trials (Herbst et al., 2006, Hotte et al., 2008). Incorporation of rhTRAIL-based 68 
therapies into multimodality regimens (e.g. chemotherapeutics, radiation, proteosomal 69 
inhibitor combinations) often demonstrates additive or synergistic efficacy (Wen et 70 
al., 2000, Belka et al., 2001). 71 
In non-human, non-rodent animal species, the TRAIL: TRAIL receptor system 72 
is not well-characterized. Orthologs for TRAIL have been predicted from the 73 
genomes of various species including horse, dog, cat and chicken. However, there 74 
appears to be considerable species variation in TNFRSF10 family members. 75 
TNFRSF10A orthologs have only been verified in primates (although predicted for 76 
cow and pig). TNFRSF10B orthologs have been found in the mouse as well as in 77 
primates and are predicted for the cat, mouse, rat, cow and pig. In contrast, the 78 
TNFRSF10C/D decoy receptors have only been identified in humans to date. 79 
TNFRSF11B does appear to be conserved and has been characterized in several 80 
species, probably due to its other roles in regulation of bone turnover (reviewed by 81 
Roodman, 2004). 82 
Mast cell tumors are the most common skin malignancy in dogs, representing 83 
up to 21% of tumors at this site, but are uncommon in other species (Brodey, 1970, 84 
Rothwell et al., 1987). Several breeds are over-represented including Boxers, English 85 
Bulldogs, Boston terriers and Chinese Shar Peis (Peters, 1969, Patnaik et al., 1984, 86 
Bostock, 1986, Rothwell et al., 1987). The median survival time post-surgery for dogs 87 
with poorly differentiated mast cell tumors has been reported at as few as 13 weeks 88 
(Bostock et al., 1989). One major factor that has been linked with an aggressive 89 
phenotype and poor prognosis is activating mutations of the stem cell factor receptor 90 
(KIT) (London et al., 1999, Ma et al., 1999, Downing et al., 2002, Zemke et al., 2002, 91 
Webster et al., 2006), which is likely to generate a pro-survival signal, protecting 92 
neoplastic cells from apoptosis. 93 
Surgery is the treatment of choice for canine mast cell tumors, but is a local 94 
therapy, and although many tumors demonstrate sensitivity to radiation and 95 
chemotherapeutics, these modalities tend to be best used in an adjuvant minimal 96 
residual disease setting (reviewed by London, 2003). Cases with disseminated or 97 
gross disease tend to respond less favorably to chemotherapy with short survival 98 
times, underlying the need to develop new therapies for these patients (O’Keefe et al., 99 
1987). The aim of the current study was to investigate whether the canine C2 100 
mastocytoma cell line, which expressed mutant KIT, was susceptible to TRAIL-101 
mediated apoptosis as the first stage in evaluating the potential of TRAIL-based 102 
therapy for mast cell tumors in dogs. 103 
 104 
2. Materials and Methods 105 
2.1 Cells and cell culture 106 
The C2 canine mastocytoma cell line (Lazarus et al., 1986) was kindly donated by 107 
Prof. B. A. Helm (University of Sheffield, UK) with permission from the originator 108 
(Prof. W Gold, University of California, USA). The MDCK cell line was obtained 109 
from the ECACC. Cells were propagated at 37 °C, 5% CO2, in 75 cm
2
 flasks (NUNC, 110 
Hereford, UK) in culture medium consisting of Eagle’s minimal essential medium, 111 
supplemented with 5% FCS, 1% non-essential amino acids, 50 μg/ml gentamicin (all 112 
Sigma-Aldrich, Poole, UK) and 1% L-glutamine (Invitrogen, Paisley, UK). For 113 
experiments, cells were dissociated using Accutase™ (PAA Laboratories, Hampshire, 114 
UK) and cultured in phenol red-free minimal essential medium (Invitrogen), 115 
supplemented with 10% FCS, 1% non-essential amino acids, 1% L-glutamine and 50 116 
μg/ml gentamicin. 117 
 118 
2.2 Quantification of apoptosis and cell metabolism 119 
For apoptosis assays, C2 or MDCK cells were cultured at 2 x 10
5
/ml in 50 μl 120 
aliquots in 96-well clear-bottomed, opaque white-walled, flat-bottomed tissue culture 121 
plates (Corning, New York, USA). For cell metabolism assays, cells were cultured at 122 
2 x 10
5
/ml in 100 μl aliquots in 96-well tissue culture plates (NUNC).  Cells were 123 
cultured with soluble rhTRAIL (R&D systems, Abingdon, UK) at the indicated 124 
concentrations in duplicate. Cells were cultured with staurosporine (Sigma-Aldrich) at 125 
100 mM as a positive control apoptosis-inducing agent. Cells cultured in medium 126 
alone were used as negative controls.  127 
Cells were incubated at 37 °C, 5% CO2 for 8 h before measuring the level of 128 
apoptosis using the Caspase 3/7 GLO assay (Promega, Southampton, UK) by adding 129 
an equal volume of the reagent to the wells containing cells. For validation of the 130 
assay, in selected wells 50 μl medium without cells was supplemented with 1 U 131 
rhCaspase 3 (BioVision, California, USA) with or without 2mM pan-caspase inhibitor 132 
(Z-VAD-FMK, R&D systems) immediately prior to addition of the reagent. After 2 h 133 
incubation, plates were analysed using a luminometer (Spectramax M2, Molecular 134 
Devices Ltd., Wokingham, UK). 135 
Cell metabolism was determined after 24 h culture using Cell Titer 96 136 
Aqueous One
TM
 (Promega).  Twenty microlitres of reagent were added per well and 137 
cells incubated for a further 2 h. Absorbance values at 490nm were obtained using a 138 
plate reader (Spectramax M2, Molecular Devices Ltd., Wokingham, UK).  139 
 140 
2.3 Flow cytometric analysis of apoptosis 141 
C2 or MDCK cells were cultured at 2 x 10
6
/ml in 100 μl aliquots in 96 well plates 142 
with medium, supplemented in selected wells with rhTRAIL (100 ng/ml) or 143 
staurosporine (100 mM).  Following incubation at 37 °C, 5% CO2 for 8 h, cells were 144 
labeled using an Annexin V:FITC antibody (Abd Serotec Ltd., Oxford, UK) and 145 
analysed by flow cytometry (FACSAria, Becton Dickinson, Erembodegem, Belgium). 146 
 147 
3.4 Polymerase chain reaction for detection of TNFRSF11B mRNA expression 148 
Polymerase chain reaction was used to amplify canine TNFRSF11B from 149 
cDNA prepared from C2 cells or MDCK cells using primers based on the predicted 150 
sequence (Genbank accession # XM_539146; sense: 5’-CTAACACAGAAAGGAAA 151 
TGCAAC-3’; antisense: 5’-TCATCGTCTTCTCAATGTCTTCT-3’). Briefly, RNA 152 
was isolated from cultured cells using the GenElute™ Mammalian Total RNA 153 
Miniprep Kit (Sigma-Aldrich). Reverse transcription of mRNA into cDNA was 154 
performed using oligo(dT)15 primer and ImProm-II reverse transcriptase (Promega). 155 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) house-keeping gene primers 156 
(Pinelli et al., 1999) were used initially to ensure that the cDNA produced was of 157 
adequate quality for PCR analysis. Each 25 μl reaction consisted of 1 l cDNA with 158 
1x NH4 buffer (16 mM), 1x Hi-Spec Additive, dNTP (final concentration 10 mM), 159 
magnesium chloride (final concentration 2.5 mM), 0.5 units Immolase 
TM
 DNA 160 
polymerase (all from Bioline, London, UK) and 1 μl each sense/antisense primers (10 161 
pmol/l final concentration).  Reactions were heated to 95˚C for 10 min, followed by 162 
35 cycles of 94˚C for 40 s, 55˚C for 30 s and 72˚C for 60 s; with a final extension step 163 
of 72˚C for 7 min.  PCR was performed using a G Storm thermocycler (Gene 164 
Technologies Ltd., Essex, UK) and products were separated by horizontal gel 165 
electrophoresis using 2% agarose (Bioline) gels containing 0.5 µg/ml SafeView 166 
Nucleic acid stain
TM
 (NBS Biologicals Huntingdon, UK).  DNA was visualized under 167 
590 nm ultra-violet light, using the ImageMaster
®
 VDS Gel Documentation System 168 
(Pharmacia Biotech, Uppsala, Sweden).   169 
 170 
3. Results 171 
Compared to MDCK cells, C2 cells demonstrated much greater caspase 3/7 activity 172 
following exposure to soluble rhTRAIL (Figure 1). Furthermore, caspase 3/7 activity 173 
could be detected in C2 cells at much lower concentrations of rhTRAIL, compared to 174 
MDCK cells, indicating a greater sensitivity to its pro-apoptotic effects. C2 cells 175 
demonstrated a consistent decrease in metabolic activity following exposure to 176 
soluble rhTRAIL whereas the metabolic activity of the MDCK cells changed little 177 
from baseline (Figure 2). 178 
Flow cytometric analysis demonstrated little difference in Annexin-V labelling 179 
comparing rhTRAIL-treated and untreated MDCK cells (Figure 3). In contrast, there 180 
was a large increase in the proportion of C2 cells labelled with Annexin-V following 181 
culture with rhTRAIL (Figure 3), suggesting enhanced levels of apoptosis in the 182 
treated cells. 183 
Only one potential canine TRAIL receptor ortholog (TNFRSF11B) could be 184 
identified by screening the dog genome assembly 185 
(http://www.ensembl.org/Canis_familiaris/index.html), with no evidence for 186 
TNFRSF10 members either by homology searching (BLAST), using protein domain-187 
prediction software (BIOMART) or a conservation of synteny-based approach. 188 
Analysis of cDNA prepared from cultured cells demonstrated that TNFRSF11B 189 
mRNA was expressed by C2 but not MDCK cells (Figure 4).  190 
 191 
4. Discussion 192 
This study shows that there are differences in the effect of soluble rhTRAIL on 193 
the two cell lines studied, with C2 cells demonstrating much greater sensitivity to 194 
apoptosis than the MDCK cell line. C2 was established from a spontaneously-195 
occurring mast cell tumor-bearing mixed-breed dog which was transplanted and 196 
propagated in BALB/c nude mice (Lazarus et al., 1986). In contrast, MDCK was 197 
established from healthy adult Cocker spaniel kidney tissue (Madin et al., 1957). 198 
Thus, there might be differences in susceptibility to the effects of TRAIL that are 199 
dependent upon whether the cell has undergone spontaneous malignant transformation 200 
or in vitro immortalization. Interestingly, human foreskin fibroblast and human 201 
embryonic kidney cells that have been immortalized using sv40 and telomerase were 202 
not susceptible to rhTRAIL-induced apoptosis, unless additionally transformed using 203 
active ras (Nesterov et al., 2004). 204 
Non-neoplastic human cells tend to express the full repertoire of TRAIL 205 
receptors whereas neoplastic cells tend to downregulate decoy receptor expression 206 
while continuing to express effector receptors (LeBlanc and Ashkenazi, 2003). Such 207 
differences in the receptor expression profile are likely to contribute to the cancer-208 
specific apoptotic effect of TRAIL on human cell lines (Meng et al., 2000). The 209 
results of the current study are consistent with differential effects of TRAIL on a cell 210 
line derived from neoplastic tissue (C2) versus one derived from normal tissue 211 
(MDCK). However, further work is required with a larger number of different cell 212 
lines derived from neoplastic and non-neoplastic tissue to test this hypothesis. 213 
There is a canine ortholog of TRAIL, located on chromosome 34 (Ensembl 214 
dog genome server: ENSCAFG00000015383). Analysis of the predicted protein 215 
sequence and structure of human and canine TRAIL shows that there is 87% identity 216 
at the amino acid level in the extracellular region containing the TNF-like domains, 217 
which likely accounts for the cross-reactivity of rhTRAIL on canine cells. The 218 
concentrations of rhTRAIL used in the current study (0.1-1000 ng/ml) are consistent 219 
with those reported in the literature, where most susceptible cell lines show an ED50 220 
between 1-100 ng/ml. 221 
Although a TRAIL ortholog was identified in the dog genome assembly, it 222 
was not possible to find any orthologs for the human TNFRSF10 family members. It 223 
was possible to locate orthologs of both the upstream (RHOBTB2) and downstream 224 
(CHMP7) genes in the dog genome assembly that flank TNFRSF10A-D in other 225 
species. The dog genome assembly is based on a Boxer dog, a breed that is 226 
predisposed to neoplastic disease, especially lymphoma and mast cell tumors 227 
(Bostock, 1986, Priester et al., 1973). The region between RHOBTB2 and CHMP7 in 228 
the human is of the order of 0.25 Mb, whereas the corresponding region in the canine 229 
genome is of the order of 0.06 Mb.  It is possible that there are canine orthologs of 230 
TNFRSF10A-D but that this region has been deleted, either in the individual Boxer 231 
dog on which the dog genome assembly was based, or in the Boxer breed as a whole. 232 
This could be a potential explanation for the predisposition of Boxers to neoplastic 233 
disease. It is interesting to note that TNFRSF10B knock-out mice are more prone to 234 
developing neoplastic diseases (Zerafa, et al. 2005, Finnberg et al., 2008).  235 
Although no canine orthologs of the human TNFRSF10 family members could 236 
be found in the dog genome assembly, a canine TNFRSF11B ortholog was identified. 237 
It does not seem likely that a TRAIL gene would be present in the dog genome and 238 
that rhTRAIL could induce apoptosis in C2 cells, without a corresponding effector 239 
receptor to carry out its biological functions. The demonstration of TNFRSF11B 240 
mRNA in the C2 cell line and not in the MDCK cell line is not consistent with the 241 
increased susceptibility of C2 cells to TRAIL-mediated apoptosis since this protein 242 
functions as a decoy receptor in other species. It is possible that canine TNFRSF11B 243 
is expressed on the cell surface rather than being secreted and so functions as a death 244 
receptor, although no recognizable transmembrane domain was found through the use 245 
of protein prediction software (http://smart.embl-heidelberg.de/). An attempt to 246 
demonstrate binding of polyhistidine-tagged rhTRAIL to the surface of C2 cells 247 
through labelling with anti-Histidine:FITC followed by flow cytometry failed (data 248 
not shown), although this is possibly due to low affinity/avidity receptor binding.  249 
At the higher doses of rhTRAIL used, sub-optimal effects were seen on 250 
caspase and metabolic activity in C2 cells, rather than a maximal plateau effect. In 251 
addition a marginal increase in metabolic activity was seen in the MDCK cells at the 252 
highest concentrations of rhTRAIL (Fig. 2). This might be consistent with dose-253 
dependent variation in intracellular signaling that influences cellular outcomes. For 254 
example, activation of NF-κB, which has been reported at higher concentrations of 255 
TRAIL, might counteract apoptosis signaling pathways (Baldwin et al., 1997, 256 
Chaudhary et al., 1997, Hu et al., 1999). 257 
Future work is warranted to more fully characterize the role of TRAIL and its 258 
potential receptors in the dog, and the importance of apoptosis effector and modulator 259 
proteins. Evaluation of several other canine neoplastic and non-neoplastic cell lines as 260 
well as primary cells from various lineages would be necessary to demonstrate the 261 
tumor cell-specific apoptotic effects of TRAIL in dogs. Should TRAIL prove to have 262 
selective anti-cancer properties in the dog, it might be a useful therapeutic molecule in 263 
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446 
Fig. 1. Caspase 3/7 activity in C2 and MDCK cells cultured with soluble rhTRAIL. 447 
Cells were cultured for 8h and caspase activity was determined using a bioassay 448 
(Caspase 3/7 GLO
TM
). Results are shown as the mean luminescence value ± SEM. 449 
The experiment was repeated twice with similar results. Controls: Med = culture 450 
medium only; Casp = culture medium supplemented with 20 U/ml rhCaspase3; 451 
Casp+inhib = culture medium supplemented with 20 U/ml rhCaspase3 and 2mM Z-452 
VAD-FMK pancaspase inhibitor. Stauro = cells cultured in the presence of 100mM 453 
staurosporine. 454 
 455 
Fig. 2. C2 and MDCK cell metabolism following exposure to soluble rhTRAIL. Cell 456 
metabolism was assessed using a metabolic assay (Cell Titer 96 Aqueous One
TM
). 457 
Results are shown as the mean ± SEM of the difference in absorbance values between 458 
cells cultured with rhTRAIL and cells in medium only.  459 
 460 
Fig. 3. Flow cytometric analysis of apoptosis in C2 and MDCK cells exposed to 461 
soluble rhTRAIL. Cells were cultured in the presence or absence of 100 ng/ml 462 
rhTRAIL for 8 h and stained with annexinV:FITC. Results are shown as fluorescence 463 
histogram overlays and mean fluorescence intensities of treated (  ) and un-treated (  ) 464 
cells. 465 
 466 
Fig. 4. Assessment of canine TNFRSF11B mRNA expression by C2 and MDCK 467 
cells.  cDNA prepared from C2 and MDCK cells was assessed for expression of 468 
TNFRSF11B by PCR using specific primers. Anticipated amplicon size = 432 base 469 
pairs. Ladder = 100 bp molecular weight ladder; H2O = water negative control 470 
template. 471 
472 
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